WALDEN BIOSCIENCES
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease.
WALDEN BIOSCIENCES
Industry:
Biotechnology Health Care Life Science
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.waldenbiosciences.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
51 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Maps Content Delivery Network
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
COMPASS Pathways
Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Alumis
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Gameto
Gameto is a biotechnology firm focused on female reproductive fertility biotech.
Glympse Bio
Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
nference
nference is an Artificial Intelligence (AI)-powered venture creation engine
Ossium Health
Ossium Health is building the world's first bone marrow bank to treat blood cancers
SNIPR Biome
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
ATEM Capital Fund LP
ATEM Capital Fund LP investment in Series B - Walden Biosciences
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Walden Biosciences
UCB Ventures
UCB Ventures investment in Series A - Walden Biosciences
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series A - Walden Biosciences
Official Site Inspections
http://www.waldenbiosciences.com Semrush global rank: 5.84 M Semrush visits lastest month: 1.21 K
- Host name: 104.18.30.199
- IP address: 104.18.30.199
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Walden Biosciences"
About - Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease.See details»
Walden Biosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts …See details»
Walden Biosciences Launches to Transform the Treatment of …
Walden Biosciences - LinkedIn
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease.See details»
Walden Biosciences - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Walden Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Walden Biosciences Announces Participation at October
Oct 13, 2022 For more information, please visit www.waldenbiosciences.com. Investor Contact: Stern Investor Relations Anne Marie Fields Managing Director [email protected]. …See details»
Walden Biosciences launches with $51M and a 2-pronged …
Oct 6, 2020 In the U.S., about 37 million people live with kidney disease, which is more than 1 in 7 American adults. But Blaine McKee, the CEO of the newly unveiled Cambridge, MA, startup …See details»
Walden Biosciences Announces Positive Topline Data from
Apr 15, 2024 For more information, please visit www.waldenbiosciences.com. Investor Contact: Stern Investor Relations Anne Marie Fields Managing Director [email protected]. …See details»
Walden Biosciences Announces First Subject Dosed in First-in …
Jun 5, 2023 Walden was launched in late 2020 with a $51 million Series A round of financing led by ARCH Venture Partners with participation from other leading venture capital firms. For …See details»
Walden Biosciences Announces First Subject Dosed in First-in
Jun 5, 2023 Walden was launched in late 2020 with a $51 million Series A round of financing led by ARCH Venture Partners with participation from other leading venture capital firms. For …See details»
Walden Biosciences Launches to Transform the Treatment of …
Oct 6, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today …See details»
Walden Biosciences Announces Research Collaboration with
Jul 5, 2022 For more information, please visit www.waldenbiosciences.com. Investor Contact: Stern Investor Relations Anne Marie Fields Managing Director [email protected]. …See details»
Walden Biosciences Announces Presentation at Antibody …
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the ...See details»
Newsroom - Walden Biosciences
Apr 15, 2024 All of Walden’s programs offer the promise to deliver disease-modifying, breakthrough therapies that are readily combinable with the standard of care to transform the …See details»
Walden Biosciences Fully Enrolls First Cohort in Phase 2 ... - BioSpace
Sep 30, 2024 Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025. CAMBRIDGE, Mass., Sept. …See details»
Walden Biosciences Announces First Subject Dosed in First-in …
Jun 5, 2023 Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete …See details»
Newsroom - Walden Biosciences
May 13, 2024 Study to further understand the established role that suPAR plays in causing kidney disease. Cambridge, MA – May 13, 2024 – Walden Biosciences, Inc. (Walden), a …See details»
Newsroom - Walden Biosciences
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney DiseasesSee details»
Walden Biosciences Fully Enrolls First Cohort in Phase 2
Sep 30, 2024 Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025. September 30, 2024 07:00 …See details»